$Novo-Nordisk A/S(NVO)$ view o

$Novo-Nordisk A/S(NVO)$ view order details.@Trade Feed Decoder

NVO

08-07 14:15

USNovo-Nordisk A/S

Side	Price \| Filled	Realized P&L
Buy Open	55.00 100	-- Closed

Novo-Nordisk A/S

Trade Feed: Who is your favorite trader?

Come to the Trade Feed Topic to find more trading opportunities! Also, please feel free to recommend and introduce fellow Tigers to the "hidden gem traders" that you've discovered!

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Trade Feed Decoder
08-07
Trade Feed Decoder
The trade involves a buy of Novo Nordisk (NVO) at $55.00. As a global leader in diabetes care and obesity treatments, Novo Nordisk’s fundamentals align with growing healthcare demand in these sectors. However, the absence of position-sizing details limits assessment of risk management. Notably, the $55 entry price appears significantly below recent market levels (current shares trade >$140), suggesting either a historical reference, data discrepancy, or potential split-adjusted price. Investors might analyze the rationale behind timing—whether tied to pipeline developments, market expansion, or valuation metrics. While the trade lacks realized P/L context, Novo’s strong revenue growth and dominant market share offer long-term appeal. Consider evaluating sector trends and risk tolerance when reviewing such positions.

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":464987457585376,"tweetId":"464987457585376","gmtCreate":1754547505984,"gmtModify":1763764417773,"author":{"id":3573671273341085,"idStr":"3573671273341085","authorId":3573671273341085,"authorIdStr":"3573671273341085","name":"pausmiling","avatar":"https://static.tigerbbs.com/951f56129924e006a4c2184505cb4172","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":26,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":24,"starInvestorOrderShareNum":199,"userFollowInvestorFlag":false,"orderNotificationFlag":false,"ror":82.44,"showRor":true,"winRationPercentage":80.41958,"tradeVolumeEst":0},"themes":[{"themeId":"4e1ab37448a24dd39b7882426fc6fd27","categoryId":"ab3d937a5fd848c08008411a9be702b5","name":"Trade Feed: Who is your favorite trader?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":4e1ab37448a24dd39b7882426fc6fd27}&rnconfig={\"headerBarHidden\": true}","description":"Come to the Trade Feed Topic to find more trading opportunities! Also, please feel free to recommend and introduce fellow Tigers to the \"hidden gem traders\" that you've discovered!","image":"https://community-static.tradeup.com/news/e496e574dd744490c7b4f7959f83f5a4"}],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$&nbsp;</a>view order details.<a href=\"https://ttm.financial/U/10000000000011061\">@Trade Feed Decoder</a></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$&nbsp;</a>view order details.<a href=\"https://ttm.financial/U/10000000000011061\">@Trade Feed Decoder</a></body></html>","text":"$Novo-Nordisk A/S(NVO)$ view order details.@Trade Feed Decoder","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":4,"favoriteSize":0,"link":"https://ttm.financial/post/464987457585376","repostId":0,"isVote":1,"tweetType":1,"viewCount":412,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["NVO"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":true,"orderData":{"uuid":"3573671273341085","orderId":"40061912353083392","kind":"TRADE","symbol":"NVO","secType":"STK","symbolHtmlTag":"<a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$&nbsp;</a>","symbolHtmlTagHref":"https://ttm.financial/S/NVO","symbolName":"Novo-Nordisk A/S","market":"US","action":"BUY","currency":"USD","symbolLogo":"https://static.tigerbbs.com/4454e2be594d73a2a7bfa9c42bfb69f7","showFilledQuantity":true,"nameCN":"Novo-Nordisk A/S","orderType":"LMT","filledQuantityFinal":100,"avgFillPrice":55,"createTime":1754547335,"filledQuantity":"100","filledQuantityScale":"0","openFlag":true,"side":"DEBIT","contractMajorDescription":"Novo-Nordisk A/S","contractExtraDescription":"NVO","legs":[],"completedFlag":true,"orderPnl":{"openRealizedPnlPercent":0.091},"quickOrderFlag":false},"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["订单分享帖","未分享订单分享帖"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":34,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":465221145231688,"commentId":"465221145231688","gmtCreate":1754551834838,"gmtModify":1754555361068,"authorId":10000000000011060,"author":{"id":10000000000011060,"idStr":"10000000000011061","authorId":10000000000011060,"name":"Trade Feed Decoder","avatar":"https://community-static.tradeup.com/news/4dc8fec78bad5acffbf563bdbc6bc8ed","vip":4,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":464987457585376,"objectIdStr":"464987457585376","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"The trade involves a buy of Novo Nordisk (NVO) at $55.00. As a global leader in diabetes care and obesity treatments, Novo Nordisk’s fundamentals align with growing healthcare demand in these sectors. However, the absence of position-sizing details limits assessment of risk management. Notably, the $55 entry price appears significantly below recent market levels (current shares trade &gt;$140), suggesting either a historical reference, data discrepancy, or potential split-adjusted price. Investors might analyze the rationale behind timing—whether tied to pipeline developments, market expansion, or valuation metrics. While the trade lacks realized P/L context, Novo’s strong revenue growth and dominant market share offer long-term appeal. Consider evaluating sector trends and risk tolerance when reviewing such positions.","text":"The trade involves a buy of Novo Nordisk (NVO) at $55.00. As a global leader in diabetes care and obesity treatments, Novo Nordisk’s fundamentals align with growing healthcare demand in these sectors. However, the absence of position-sizing details limits assessment of risk management. Notably, the $55 entry price appears significantly below recent market levels (current shares trade &gt;$140), suggesting either a historical reference, data discrepancy, or potential split-adjusted price. Investors might analyze the rationale behind timing—whether tied to pipeline developments, market expansion, or valuation metrics. While the trade lacks realized P/L context, Novo’s strong revenue growth and dominant market share offer long-term appeal. Consider evaluating sector trends and risk tolerance when reviewing such positions.","html":"The trade involves a buy of Novo Nordisk (NVO) at $55.00. As a global leader in diabetes care and obesity treatments, Novo Nordisk’s fundamentals align with growing healthcare demand in these sectors. However, the absence of position-sizing details limits assessment of risk management. Notably, the $55 entry price appears significantly below recent market levels (current shares trade &gt;$140), suggesting either a historical reference, data discrepancy, or potential split-adjusted price. Investors might analyze the rationale behind timing—whether tied to pipeline developments, market expansion, or valuation metrics. While the trade lacks realized P/L context, Novo’s strong revenue growth and dominant market share offer long-term appeal. Consider evaluating sector trends and risk tolerance when reviewing such positions.","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"hot","coins":0,"score":0,"disclaimerFlag":true,"disclaimerType":1,"specialCommentTag":"AI_ANALYSE"}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/464987457585376"}